文献速递头颈与中枢神经肿瘤

大唾液腺癌远处转移临床预测评分模型的开发与验证

Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma.
PubMed 文献 · Ann Oncol · 2019-12-16

该研究基于四个三级癌症中心接受根治性治疗的大唾液腺癌患者,开发并验证了一个远处转移预测评分模型。发现队列619例中,阳性切缘、pT3-4、pN+、淋巴血管侵犯和高危组织学为预测因素,评分大于2定义为高危;高危与低危患者5年远处转移发生率分别为50%与8%(P<0.01),验证队列中为44%与4%(P<0.01)。该模型可用于识别远处转移高风险患者。

要点

  • 评分因素包括阳性切缘、pT3-4、pN+、淋巴血管侵犯和高危组织学。
  • 评分总和大于2定义为高危大唾液腺癌。
  • 高危患者5年远处转移发生率显著高于低危患者。

核心结论

  • 该验证的预测评分模型可用于识别大唾液腺癌远处转移高风险患者,并筛选可能受益于治疗强化和/或监测策略前瞻性评估的患者。

研究设计与样本

  • 研究纳入四个三级癌症中心接受根治性治疗的大唾液腺癌患者,分为发现队列(n=619)和验证队列(n=416)。
  • 采用竞争风险回归多变量分析识别远处转移预测因素并建立评分,采用最小P值法确定最佳截断值。

主要发现

  • 发现队列中远处转移预测因素及风险系数为:阳性切缘(0.6)、pT3-4(0.7)、pN+(0.7)、淋巴血管侵犯(0.8)、高危组织学(1.2)。
  • 发现队列中高危与低危患者5年远处转移发生率分别为50%与8%(P<0.01),验证队列中分别为44%与4%(P<0.01)。
  • 合并队列中,模型对远处-only失败(40% vs 6%,P<0.01)和晚期(术后>2年)远处转移(22% vs 4%,P<0.01)预测表现相似。
  • 接受术后放疗亚组中,高危患者远处转移发生率更高(46% vs 8%,P<0.01)。
  • 高危与低危患者5年总生存率分别为48%与92%(P<0.01)。

关键数值与推荐

  • 高危大唾液腺癌定义为风险系数总和大于2。
  • 5年远处转移发生率:发现队列高危50% vs 低危8%(P<0.01);验证队列高危44% vs 低危4%(P<0.01)。
  • 5年总生存率:高危48% vs 低危92%(P<0.01)。

临床怎么用

  • 可利用该评分模型识别大唾液腺癌远处转移高风险患者,以便个体化考虑治疗强化和/或监测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The most common pattern of failure in major salivary gland carcinoma (SGC) is development of distant metastases (DMs). The objective of this study was to develop and validate a prediction score for DM in SGC. PATIENTS AND METHODS: Patients with SGC treated curatively at four tertiary cancer centers were divided into discovery (n = 619) and validation cohorts (n = 416). Multivariable analysis using competing risk regression was used to identify predictors of DM in the discovery cohort and create a prediction score of DM; the optimal score cut-off was determined using a minimal P value approach. The prediction score was subsequently evaluated in the validation cohort. The cumulative incidence and Kaplan-Meier methods were used to analyze DM and overall survival (OS), respectively. RESULTS: In the discovery cohort, DM predictors (risk coefficient) were: positive margin (0.6), pT3-4 (0.7), pN+ (0.7), lymphovascular invasion (0.8), and high-risk histology (1.2). High DM-risk SGC was defined by sum of coefficients greater than two. In the discovery cohort, the 5-year incidence of DM for high- versus low-risk SGC was 50% versus 8% (P < 0.01); this was similar in the validation cohort (44% versus 4%; P < 0.01). In the pooled cohorts, this model performed similarly in predicting distant-only failure (40% versus 6%, P < 0.01) and late (>2 years post surgery) DM (22% versus 4%; P < 0.01). Patients with high-risk SGC had an increased incidence of DM in the subgroup receiving postoperative radiation therapy (46% versus 8%; P < 0.01). The 5-year OS for high- versus low-risk SGC was 48% versus 92% (P < 0.01). CONCLUSION: This validated prediction-score model may be used to identify SGC patients at increased risk for DM and select those who may benefit from prospective evaluation of treatment intensification and/or surveillance strategies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lukovic J, Alfaraj FA, Mierzwa ML, et al. Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma. Ann Oncol. 2019. PMID: 31959347. doi:10.1016/j.annonc.2019.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。